1. Search Result
Search Result
Results for "

glutaric

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Biochemical Assay Reagents

8

Natural
Products

8

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W008820

    Endogenous Metabolite Metabolic Disease
    Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .
    Glutaric acid
  • HY-W008820S

    Endogenous Metabolite Metabolic Disease
    Glutaric acid-d6 is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
    Glutaric acid-d6
  • HY-W008820S1

    Endogenous Metabolite Metabolic Disease
    Glutaric acid-d4 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
    Glutaric acid-d4
  • HY-113005

    Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
    Glutarylcarnitine
  • HY-113005A

    Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes .
    Glutarylcarnitine lithium
  • HY-W008820S2

    Endogenous Metabolite Metabolic Disease
    Glutaric acid-d2 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
    Glutaric acid-d2
  • HY-W008820R

    Endogenous Metabolite Metabolic Disease
    Glutaric acid (Standard) is the analytical standard of Glutaric acid. This product is intended for research and analytical applications. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I . In Vitro: Glutaric acid (GA) at concentrations of 1 and 2 mM is able to reduce TRAP measurement by up to 28% in a dose-dependent manner (β=0.77; P<0.001). Furthermore, a significantly inverse correlation is also verified between chemiluminescence and TRAP (β=0.81; P<0.001). Glutaric acid does not alter the activities of Cat and SOD, but strongly inhibits (up to 46%) the activity of GPx even at the lower concentration used (0.5 mM). It is observed that the metabolite inhibits this activity in a dose-dependent manner at concentrations as low as 0.05 mM .
    Glutaric acid (Standard)
  • HY-41880S

    Dihydro-2H-pyran-2,6(3H)-dione-d6; Dihydro-3H-pyran-2,6-dione-d6; glutaric acid anhydride-d6

    Isotope-Labeled Compounds Others
    Glutaric anhydride-d6 is the deuterium labeled Glutaric anhydride[1].
    Glutaric anhydride-d6
  • HY-W441006

    Liposome Others
    DSPE-glutaric acid is a lipid. DSPE-glutaric acid can be used for the research of various biochemical .
    DSPE-glutaric acid
  • HY-139070

    Endogenous Metabolite Metabolic Disease
    D-Glyceric acid is an endogenous metabolite present in urine that can be used for the research of primary hyperoxaluria type I and glutaric acidemia type 2 .
    D-Glyceric acid
  • HY-139070A

    Endogenous Metabolite Metabolic Disease
    D-Glyceric acid sodium is the sodium form of D-Glyceric acid (HY-139070A). D-Glyceric acid is an endogenous metabolite present in urine that can be used for the research of primary hyperoxaluria type I and glutaric acidemia type 2 .
    D-Glyceric acid sodium
  • HY-113411

    Endogenous Metabolite Others
    3-Hydroxyglutaric acid is a glutaric acid derivative.
    3-Hydroxyglutaric acid
  • HY-113411S

    Endogenous Metabolite Others
    3-Hydroxyglutaric acid-d5 is the deuterium labeled 3-Hydroxyglutaric acid. 3-Hydroxyglutaric acid is a glutaric acid derivative[1][2].
    3-Hydroxyglutaric acid-d5
  • HY-113005S

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine-d9 (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
    Glutarylcarnitine-d9 chloride
  • HY-113038B

    2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid

    Histone Demethylase Endogenous Metabolite Cancer
    α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases .
    α-Hydroxyglutaric acid
  • HY-113038A

    2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium

    Histone Demethylase Endogenous Metabolite Cancer
    α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases .
    α-Hydroxyglutaric acid disodium
  • HY-113038AS

    2-Hydroxyglutarate-13C5 disodium; 2-Hydroxyglutaric acid-13C5 sodium; 2-Hydroxypentanedioic acid-13C5 disodium

    Histone Demethylase Endogenous Metabolite Cancer
    α-Hydroxyglutaric acid- 13C5 (sodium) is the 13C labeled α-Hydroxyglutaric acid sodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) sodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid sodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].
    α-Hydroxyglutaric acid-13C5 disodium
  • HY-113038AS1

    2-Hydroxyglutarate-d4 disodium; 2-Hydroxyglutaric acid-d4 disodium; 2-Hydroxypentanedioic acid-d4 disodium

    Histone Demethylase Endogenous Metabolite Cancer
    α-Hydroxyglutaric acid-d4 (disodium) is the deuterium labeled α-Hydroxyglutaric acid disodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].
    α-Hydroxyglutaric acid-d4 disodium
  • HY-121659

    Others Cancer
    DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor for small animal positron emission tomography (PET) imaging. [18F]DCFBC was prepared by reacting fluorine-18 labeled phenyl bromide with the precursor (S)-2-[3-[(R)-1-carboxy-2-thiolethyl]urea]-glutaric acid in ammonia-saturated methanol at 60°C for 10 min and then purified by C-18 reversed-phase HPLC. [18F]DCFBC was injected via the tail vein in severe combined immunodeficient mice for in vitro biodistribution or imaging. For in vitro biodistribution studies, mice were sacrificed at 5, 15, 30, 60, and 120 min after injection, and tumors, blood, and major organs were collected, weighed, and radioactivity was counted. Imaging was performed using a GE eXploreVista small animal PET scanner, collecting 12 consecutive 10-min frames. Results showed that the radiochemical yield of [18F]DCFBC averaged 16±6% (n=8) from 4-[18F]fluorophenyl bromide. Specific radioactivity ranged from 13 to 133 GBq/Amol (350-3600 Curie/mmol) with an average of 52 GBq/Amol (1392 Curie/mmol; n=6). Biodistribution and imaging studies showed high uptake of [18F]DCFBC in PIP tumors and almost no uptake in FLU tumors. High radiopharmaceutical uptake was also seen in the kidney and bladder; however, radioactivity washout from these organs was faster than from the PIP tumors. Maximum PIP tumor uptake was reached at 60 min post-injection at 8.16±2.55% injected dose/g and decreased to 4.69±0.89 at 120 min post-injection. The PIP tumor-to-muscle ratio was 20 at 120 min post-injection. Based on mouse biodistribution, the dose-limiting organ was the kidney (estimated human absorbed dose: 0.05 mGy/MBq; 0.2 rad/mCi). Conclusions: [18F]DCFBC localizes specifically to PSMA+ expressing tumors in mice and is suitable for small animal PET imaging. This novel radiopharmaceutical is an attractive candidate for further study in PET imaging of prostate cancer.
    DCFBC

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: